D. Boral Capital Reaffirms “Buy” Rating for Lineage Cell Therapeutics (NYSEAMERICAN:LCTX)

D. Boral Capital reaffirmed their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) in a report released on Friday morning,Benzinga reports. The brokerage currently has a $2.00 price objective on the stock.

Separately, HC Wainwright boosted their price objective on Lineage Cell Therapeutics from $7.00 to $9.00 and gave the stock a “buy” rating in a research report on Wednesday, December 4th.

Lineage Cell Therapeutics Stock Up 14.6 %

LCTX opened at $0.59 on Friday. The firm has a market cap of $130.07 million, a P/E ratio of -4.92 and a beta of 1.16. Lineage Cell Therapeutics has a 12 month low of $0.48 and a 12 month high of $1.61.

Hedge Funds Weigh In On Lineage Cell Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC acquired a new position in Lineage Cell Therapeutics in the third quarter valued at $46,000. XTX Topco Ltd purchased a new position in Lineage Cell Therapeutics during the 2nd quarter worth approximately $61,000. GSA Capital Partners LLP purchased a new position in Lineage Cell Therapeutics during the 3rd quarter worth approximately $84,000. Rhumbline Advisers increased its position in Lineage Cell Therapeutics by 15.1% during the second quarter. Rhumbline Advisers now owns 132,491 shares of the company’s stock worth $132,000 after buying an additional 17,411 shares during the period. Finally, Barclays PLC lifted its stake in Lineage Cell Therapeutics by 311.3% in the third quarter. Barclays PLC now owns 211,300 shares of the company’s stock valued at $192,000 after buying an additional 159,924 shares during the last quarter. 62.47% of the stock is owned by institutional investors and hedge funds.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc, a clinical-stage biotechnology company, develops novel cell therapies for unmet medical needs in the United States and internationally. The company develops OpRegen, an allogeneic retinal pigment epithelium cell replacement therapy, which is in Phase 2a clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an allogeneic oligodendrocyte progenitor cell therapy that is in Phase 1/2a multicenter clinical trial for the treatment of cervical spinal cord injuries; and VAC, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer.